Table 1—

Randomized trials that examined incidence of new-onset diabetes

TrialPrimary treatmentIncrease in new-onset diabetes by primary treatmentComparator
SHEPPlacebo↓ 5%Thiazide diuretic ± BB
STOP-2BB/thiazide diureticNo difference from comparatorACEI/CCB
CAPPPThiazide diuretic/BB↑ 13%ACEI
HOPEPlacebo ± BB/thiazide diuretic↑ 52%ACEI
INSIGHTThiazide diuretic/BB↑ 43%DHP-CCB
LIFEBB/thiazide diuretic↑ 32%ARB ± thiazide diuretic
ALLHATThiazide diuretic↑ 16%/30%DHP-CCB/ACEI
INVESTBB ± thiazide diuretic↑ 17%Non–DHP-CCB based
CHARMPlacebo ± BB/thiazide diuretic↑ 17%ARB ± BB/thiazide diuretic
VALUEDHP-CCB↑ 25%ARB based
ASCOTBB ± thiazide diuretic↑ 32%DHP-CCB based
  • ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; BB, β-blocker; CAPP, Captopril Prevention Project; CHARM, Candesartan Cilexetil (Candesartan) in Heart Failure: Assessment of Reduction in Mortality and Morbidity; DHP, dihydropyridine; HOPE, Heart Outcomes Prevention Evaluation; INSIGHT, Intervention as a Goal in Hypertension Treatment; INVEST, International Verapamil-Trandolapril Study; LIFE, Losartan Intervention For Endpoint reduction in hypertension; VALUE, Valsartan Antihypertensive Long-Term Use Evaluation.